Biomarin Pharmaceutical Inc (BMRN) earnings
Quarterly results of Biomarin Pharmaceutical Inc as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Biomarin Pharmaceutical Inc is expected to report around January 11, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.
Latest quarter: Q3 FY2026
In Q3 FY2026 (ended September 30, 2026) Biomarin Pharmaceutical Inc reported revenue of $1B (+32% on the same quarter a year earlier) and a net loss of $122.8M.
Diluted earnings per share were -$0.63.
The latest results release
BioMarin expects third-quarter and full-year 2026 earnings to be reduced by charges related to its acquisition of Alesta Therapeutics.
BioMarin completed the acquisition of Alesta Therapeutics on August 31, 2026.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | $1B | +32% | -$122.8M | -$0.63 |
| Q2 FY2026 | $989.7M | +19.9% | $44.8M | $0.23 |
| Q1 FY2026 | $766.2M | +2.8% | $105.5M | $0.54 |
| Q4 FY2025 | $874.6M | +17% | -$46.6M | - |
| Q3 FY2025 | $776.1M | - | -$30.7M | -$0.16 |
| Q2 FY2025 | $825.4M | - | $240.5M | $1.23 |
| Q1 FY2025 | $745.1M | - | $185.7M | $0.95 |
| Q4 FY2024 | $747.3M | - | $124.9M | - |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
When is Biomarin Pharmaceutical Inc's next earnings date?
Biomarin Pharmaceutical Inc is expected to report around January 11, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.
What were Biomarin Pharmaceutical Inc's latest quarterly results?
For Q3 FY2026, which ended September 30, 2026, Biomarin Pharmaceutical Inc reported revenue of $1B and a net loss of $122.8M. The figures come from its filing with the SEC.
Is Biomarin Pharmaceutical Inc's revenue growing?
Revenue in Q3 FY2026 was $1B, up 32% from $776.1M in the same quarter a year earlier.
Get an email when BMRN reports
Follow BMRN and we email you its next results the day they are filed, with the numbers explained.